FR2684999A1 - Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag. - Google Patents
Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag. Download PDFInfo
- Publication number
- FR2684999A1 FR2684999A1 FR9115601A FR9115601A FR2684999A1 FR 2684999 A1 FR2684999 A1 FR 2684999A1 FR 9115601 A FR9115601 A FR 9115601A FR 9115601 A FR9115601 A FR 9115601A FR 2684999 A1 FR2684999 A1 FR 2684999A1
- Authority
- FR
- France
- Prior art keywords
- factor vii
- activated
- factors
- vii
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940012413 factor vii Drugs 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 30
- 230000001419 dependent effect Effects 0.000 title claims abstract description 20
- 239000012141 concentrate Substances 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 7
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 title 1
- 108010054265 Factor VIIa Proteins 0.000 claims abstract description 35
- 102100023804 Coagulation factor VII Human genes 0.000 claims abstract description 34
- 108010023321 Factor VII Proteins 0.000 claims abstract description 34
- 229930003448 Vitamin K Natural products 0.000 claims abstract description 19
- 230000004913 activation Effects 0.000 claims abstract description 19
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 19
- 239000011712 vitamin K Substances 0.000 claims abstract description 19
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 19
- 229940046010 vitamin k Drugs 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 241000282414 Homo sapiens Species 0.000 claims abstract description 10
- 238000000746 purification Methods 0.000 claims abstract description 10
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 4
- 230000000694 effects Effects 0.000 claims abstract description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 13
- 229920002307 Dextran Polymers 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 12
- 238000001179 sorption measurement Methods 0.000 claims description 12
- 239000001509 sodium citrate Substances 0.000 claims description 11
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 11
- 229940038773 trisodium citrate Drugs 0.000 claims description 11
- 238000003795 desorption Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 10
- 239000007853 buffer solution Substances 0.000 claims description 9
- 239000011324 bead Substances 0.000 claims description 8
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims description 7
- 229920000136 polysorbate Polymers 0.000 claims description 7
- 239000012564 Q sepharose fast flow resin Substances 0.000 claims description 6
- 230000002779 inactivation Effects 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 150000001412 amines Chemical group 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 2
- 238000005349 anion exchange Methods 0.000 claims description 2
- 238000005571 anion exchange chromatography Methods 0.000 claims description 2
- 239000003957 anion exchange resin Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000005342 ion exchange Methods 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 101000856746 Bos taurus Cytochrome c oxidase subunit 7A1, mitochondrial Proteins 0.000 abstract description 12
- 239000006228 supernatant Substances 0.000 abstract description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 abstract 1
- 229940012414 factor viia Drugs 0.000 abstract 1
- 239000003456 ion exchange resin Substances 0.000 abstract 1
- 229920003303 ion-exchange polymer Polymers 0.000 abstract 1
- 229960002086 dextran Drugs 0.000 description 9
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 6
- 108010000499 Thromboplastin Proteins 0.000 description 6
- 102000002262 Thromboplastin Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 5
- 230000002885 thrombogenetic effect Effects 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 102000004411 Antithrombin III Human genes 0.000 description 2
- 108090000935 Antithrombin III Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 108010075016 Ceruloplasmin Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108010071241 Factor XIIa Proteins 0.000 description 2
- 108060005987 Kallikrein Proteins 0.000 description 2
- 102000001399 Kallikrein Human genes 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 108010018823 anti-inhibitor coagulant complex Proteins 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940105776 factor viii inhibitor bypassing activity Drugs 0.000 description 2
- -1 hydroxy- Chemical class 0.000 description 2
- 230000000937 inactivator Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9115601A FR2684999A1 (fr) | 1991-12-16 | 1991-12-16 | Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag. |
| ES92403234T ES2056782T3 (es) | 1991-12-16 | 1992-12-01 | Procedimiento de fabricacion de un concentrado de factor vii activado de alta pureza. |
| AT92403234T ATE142255T1 (de) | 1991-12-16 | 1992-12-01 | Verfahren zur herstellung eines aktivierten faktor vii-konzentrates mit einer hohen reinheit |
| DK92403234.5T DK0547932T3 (da) | 1991-12-16 | 1992-12-01 | Fremgangsmåde til fremstilling af et koncentrat af aktiveret faktor VII med høj renhed |
| EP92403234A EP0547932B1 (fr) | 1991-12-16 | 1992-12-01 | Procédé de fabrication d'un concentré de facteur VII activé de haute pureté |
| DE69213421T DE69213421T2 (de) | 1991-12-16 | 1992-12-01 | Verfahren zur Herstellung eines aktivierten Faktor VII-Konzentrates mit einer hohen Reinheit |
| DE92403234T DE547932T1 (de) | 1991-12-16 | 1992-12-01 | Verfahren zur Herstellung eines aktivierten Faktor VII-Konzentrates mit einer hohen Reinheit. |
| US07/988,776 US5344918A (en) | 1991-12-16 | 1992-12-10 | Process for the manufacture of a high-purity activated factor VII concentrate essentially free of vitamin K-dependent factors and factors VIIIC and VIIICAg |
| JP4354440A JP2533050B2 (ja) | 1991-12-16 | 1992-12-16 | 高純度活性因子ＶＩＩａの濃縮物の製造方法 |
| GR930300094T GR930300094T1 (en) | 1991-12-16 | 1993-09-30 | Process for preparing an activated factor VII concentrate having a high purity |
| GR960403286T GR3021875T3 (en) | 1991-12-16 | 1996-12-04 | Process for preparing an activated factor VII concentrate having a high purity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9115601A FR2684999A1 (fr) | 1991-12-16 | 1991-12-16 | Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2684999A1 true FR2684999A1 (fr) | 1993-06-18 |
| FR2684999B1 FR2684999B1 (enExample) | 1995-05-05 |
Family
ID=9420096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9115601A Granted FR2684999A1 (fr) | 1991-12-16 | 1991-12-16 | Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5344918A (enExample) |
| EP (1) | EP0547932B1 (enExample) |
| JP (1) | JP2533050B2 (enExample) |
| AT (1) | ATE142255T1 (enExample) |
| DE (2) | DE69213421T2 (enExample) |
| DK (1) | DK0547932T3 (enExample) |
| ES (1) | ES2056782T3 (enExample) |
| FR (1) | FR2684999A1 (enExample) |
| GR (2) | GR930300094T1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5664362A (en) * | 1993-09-03 | 1997-09-09 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Fishing lure which releases the involuntary biting reflex of largemouth bass and other fishes within the family centrachidae |
| DE19538716A1 (de) * | 1995-10-18 | 1997-04-24 | Behringwerke Ag | Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa) |
| DE19531637A1 (de) * | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
| DE19538715A1 (de) | 1995-10-18 | 1997-04-30 | Behringwerke Ag | Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII |
| AU781741B2 (en) * | 1998-04-24 | 2005-06-09 | Csl Behring Gmbh | Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography |
| AT408613B (de) | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
| US7498156B2 (en) | 1998-07-21 | 2009-03-03 | Caridianbct Biotechnologies, Llc | Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components |
| US7049110B2 (en) | 1998-07-21 | 2006-05-23 | Gambro, Inc. | Inactivation of West Nile virus and malaria using photosensitizers |
| US6277337B1 (en) | 1998-07-21 | 2001-08-21 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
| US6258577B1 (en) | 1998-07-21 | 2001-07-10 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| US6444788B1 (en) * | 1999-03-15 | 2002-09-03 | Novo Nordisk A/S | Ion exchange chromatography of GLP-1, analogs and derivatives thereof |
| US7094378B1 (en) | 2000-06-15 | 2006-08-22 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
| US7220747B2 (en) | 1999-07-20 | 2007-05-22 | Gambro, Inc. | Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer |
| DE19937218A1 (de) | 1999-08-06 | 2001-02-08 | Aventis Behring Gmbh | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie |
| US6268120B1 (en) | 1999-10-19 | 2001-07-31 | Gambro, Inc. | Isoalloxazine derivatives to neutralize biological contaminants |
| US7648699B2 (en) | 2000-06-02 | 2010-01-19 | Caridianbct Biotechnologies, Llc | Preventing transfusion related complications in a recipient of a blood transfusion |
| US7985588B2 (en) | 2000-06-02 | 2011-07-26 | Caridianbct Biotechnologies, Llc | Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light |
| TW590780B (en) | 2000-06-02 | 2004-06-11 | Gambro Inc | Additive solutions containing riboflavin |
| US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
| BR0215216A (pt) | 2001-12-21 | 2004-11-16 | Novo Nordisk Healthcare Ag | Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii |
| JP4648002B2 (ja) | 2002-06-21 | 2011-03-09 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第ｖｉｉ因子ポリペプチドの安定化された固体組成物 |
| CN1761747A (zh) * | 2003-03-18 | 2006-04-19 | 诺和诺德医疗保健公司 | 生产含有gla残基的丝氨酸蛋白酶的方法 |
| US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
| DE602004025100D1 (de) | 2003-05-23 | 2010-03-04 | Novo Nordisk Healthcare Ag | Stabilisierung von proteinen in lösung |
| ES2382157T3 (es) | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Composición líquida de polipépttidos del factor VII |
| KR101293503B1 (ko) | 2003-08-14 | 2013-08-07 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물 |
| WO2005019261A1 (en) * | 2003-08-21 | 2005-03-03 | Novo Nordisk A/S | Separation of polypeptides comprising a racemized amino acid |
| AU2004298789A1 (en) | 2003-12-19 | 2005-06-30 | Novo Nordisk Health Care Ag | Stabilised compositions of factor VII polypeptides |
| EP1797122A2 (en) * | 2004-09-29 | 2007-06-20 | Novo Nordisk Health Care AG | Purification of a drug substance of a factor vii polypeptide by removal of desgla-factor vii polypeptide structures |
| ES2257225B1 (es) * | 2006-02-17 | 2007-03-16 | Grifols, S.A | Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion. |
| FR2901707B1 (fr) * | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
| FR2904558B1 (fr) * | 2006-08-01 | 2008-10-17 | Lab Francais Du Fractionnement | "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees" |
| FR2917414B1 (fr) * | 2007-06-15 | 2012-07-13 | Lab Francais Du Fractionnement | Facteur vii/viia humain modifie et composition pharmaceutique contenant celui-ci |
| FR2942231B1 (fr) | 2009-02-19 | 2015-03-20 | Lfb Biotechnologies | Acides nucleiques se liant specifiquement au facteur vii/viia humain, et utilisations |
| JP6088435B2 (ja) | 2010-12-15 | 2017-03-01 | バクスアルタ ゲーエムベーハー | 導電率グラディエントを用いる溶出液収集 |
| EP2687595B1 (en) | 2012-07-19 | 2018-05-30 | Laboratoire Français du Fractionnement et des Biotechnologies | Method for purifying transgenic factor VII |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4473553A (en) * | 1983-12-02 | 1984-09-25 | Miles Laboratories, Inc. | Process for producing a lipoprotein-poor concentrate of coagulation factors VII and VIIa |
| EP0346241A1 (fr) * | 1988-06-09 | 1989-12-13 | Fondation Nationale De Transfusion Sanguine | Procédé de préparation d'une fraction concentrée en facteur Vlla et son application à titre de médicament |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5314604B2 (enExample) * | 1972-12-20 | 1978-05-18 | ||
| JPS57206620A (en) * | 1981-06-12 | 1982-12-18 | Cutter Lab | Blood coagulation promoter and manufacture |
| US4540473A (en) * | 1983-11-22 | 1985-09-10 | International Business Machines Corporation | Copper plating bath having increased plating rate, and method |
| US4470969A (en) * | 1983-12-02 | 1984-09-11 | Miles Laboratories, Inc. | Process for producing a concentrate of coagulation factors VII and VIIa |
-
1991
- 1991-12-16 FR FR9115601A patent/FR2684999A1/fr active Granted
-
1992
- 1992-12-01 DE DE69213421T patent/DE69213421T2/de not_active Expired - Lifetime
- 1992-12-01 DE DE92403234T patent/DE547932T1/de active Pending
- 1992-12-01 ES ES92403234T patent/ES2056782T3/es not_active Expired - Lifetime
- 1992-12-01 DK DK92403234.5T patent/DK0547932T3/da active
- 1992-12-01 AT AT92403234T patent/ATE142255T1/de active
- 1992-12-01 EP EP92403234A patent/EP0547932B1/fr not_active Expired - Lifetime
- 1992-12-10 US US07/988,776 patent/US5344918A/en not_active Expired - Lifetime
- 1992-12-16 JP JP4354440A patent/JP2533050B2/ja not_active Expired - Fee Related
-
1993
- 1993-09-30 GR GR930300094T patent/GR930300094T1/el unknown
-
1996
- 1996-12-04 GR GR960403286T patent/GR3021875T3/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4473553A (en) * | 1983-12-02 | 1984-09-25 | Miles Laboratories, Inc. | Process for producing a lipoprotein-poor concentrate of coagulation factors VII and VIIa |
| EP0346241A1 (fr) * | 1988-06-09 | 1989-12-13 | Fondation Nationale De Transfusion Sanguine | Procédé de préparation d'une fraction concentrée en facteur Vlla et son application à titre de médicament |
Non-Patent Citations (1)
| Title |
|---|
| RESEARCH DISCLOSURE. vol. 269, Septembre 1986, HAVANT GB pages 564 - 565; S. BJOERN ET AL.: 'ACTIVATION OF COAGULATION FACTOR VII TO VIIa.' * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2056782T3 (es) | 1997-02-16 |
| DE69213421T2 (de) | 1997-04-03 |
| FR2684999B1 (enExample) | 1995-05-05 |
| DE547932T1 (de) | 1994-02-03 |
| EP0547932A1 (fr) | 1993-06-23 |
| GR930300094T1 (en) | 1993-09-30 |
| ES2056782T1 (es) | 1994-10-16 |
| GR3021875T3 (en) | 1997-03-31 |
| ATE142255T1 (de) | 1996-09-15 |
| JPH05345799A (ja) | 1993-12-27 |
| US5344918A (en) | 1994-09-06 |
| DK0547932T3 (da) | 1997-02-10 |
| EP0547932B1 (fr) | 1996-09-04 |
| JP2533050B2 (ja) | 1996-09-11 |
| DE69213421D1 (de) | 1996-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2684999A1 (fr) | Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag. | |
| EP0317376B1 (fr) | Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques | |
| CA2073734C (fr) | Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique | |
| JP3701028B2 (ja) | 高純度フォンビルブラント因子の入手方法 | |
| JP3787154B2 (ja) | Ｖｉｉｉ因子の精製方法 | |
| JP2000506869A (ja) | 安定な因子ｖｉｉｉ／▲下ｖ▼ｗｆ複合体 | |
| EP0346241B1 (fr) | Procédé de préparation d'une fraction concentrée en facteur Vlla et son application à titre de médicament | |
| HUT72712A (en) | Purification of factor vii | |
| US6043215A (en) | Preparation of factor IX | |
| JP2000508918A (ja) | 精製されたマルチメラーゼ | |
| JP4741178B2 (ja) | Ｖｉｉｉ因子：ｃ含有フォンビルブラント因子の濃縮物およびそれに関連する方法 | |
| KR100383063B1 (ko) | 사람활성화단백질c제제및이의제조방법 | |
| JPH07126184A (ja) | プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物 | |
| US5945103A (en) | Process for producing thrombin | |
| AU635298B2 (en) | Process for the preparation of a stable factor v111 | |
| EP2501401A1 (fr) | Procede de purification de facteur b | |
| JPH10150980A (ja) | プロトロンビンの精製方法 | |
| CA2030783A1 (fr) | Procede de preparation de la proteine c activee et solution de proteine c activee ainsi obtenue | |
| KANEKO et al. | Studies on acrosin. I. Purification and characterization of boar acrosin | |
| JP2007068497A (ja) | プラスミンの精製法 | |
| KR950013455B1 (ko) | 순수한 인 혈액 응고 제 2 인자 및 제 9 인자의 정제 방법 | |
| TWI245637B (en) | Stable factor VIII compositions | |
| FR2622108A1 (fr) | Preparation de concentres de proconvertine (facteur vii), de facteur antihemophilique b (facteur ix) et d'autres proteines plasmatiques, et leur utilisation therapeutique |